Class Action Lawsuit Filed Against Unicycive Therapeutics Over Alleged Securities Fraud
A class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) by the Rosen Law Firm on behalf of investors who purchased its securities between December 29, 2025 and June 29, 2026. The suit alleges that company executives made materially false or misleading statements regarding their third-party manufacturing vendor's compliance with FDA standards and failed to disclose risks related to the approval process for oxylanthanum carbonate (OLC). These alleged misrepresentations are said to have misled investors before being revealed, causing financial harm. The Rosen Law Firm is seeking lead plaintiffs who can represent other class members in directing the litigation. Investors may join the case without upfront costs through a contingency fee arrangement. The deadline for submitting claims as lead plaintiff is November 2, 2026. No class has yet been certified, and investors are advised to consult legal counsel if they wish to participate. The firm highlights its experience in securities litigation with notable past settlements, including the largest ever against a Chinese company.
